|Defined daily dose||not established|
Isoniazid/pyridoxine/sulfamethoxazole/trimethoprim (INH/B6/CTX) is a fixed dose combination medication for the prevention of opportunistic infections in HIV/AIDS. It combines isoniazid, pyridoxine, sulfamethoxazole, and trimethoprim. Specifically it is used to prevent tuberculosis, toxoplasmosis, pneumonia, malaria, and isosporiasis. It is taken by mouth.
Side effects may include trouble concentrating, numbness, vomiting, and rash. Serious side effects may include liver problems. Caution may be required in people with G6PD deficiency. While it has not been well studied, use in pregnancy appears to be okay.
It is on the World Health Organization's List of Essential Medicines. A year of medication is estimated to cost about US$15 in the developing world as of 2016. While benefits include being able to take less pills, it is unclear if this version changes peoples adherence to treatment. Other studies, however, have found fixed dose combinations to be useful for this purpose.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 11 September 2020. CS1 maint: discouraged parameter (link)
- "Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim (New formulation) -- Adults". World Health Organization (WHO). Retrieved 13 December 2017. CS1 maint: discouraged parameter (link)